Recruiting OBSERVATIONAL NCT06613165
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer
Exploring the Treatment Duration of PD-1 Neoadjuvant Therapy in Stage II-III dMMR Rectal Cancer: a Prospective，Multicentre, Single-arm Study
Sponsor: Xijing Hospital
Updated 2 times since 2024 Last updated: Dec 22, 2024 Started: Jan 1, 2025 Primary completion: Sep 20, 2026 Completion: Sep 20, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A observational or N/A phase clinical study on Immune-related Adverse Event and Neoadjuvant Therapy, this trial is actively recruiting participants. The trial is conducted by Xijing Hospital and has accumulated 2 data snapshots since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
2 versions recorded-
Jan 2025 — Present [monthly]
Recruiting
-
Oct 2024 — Jan 2025 [monthly]
Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Xijing Hospital
Data source: Xijing Hospital
For direct contact, visit the study record on ClinicalTrials.gov .